13. Netspot

FDA sign

Active ingredient: gallium Ga 68 dotatate
Disease: for the diagnostic imaging of rare neuroendocrine tumors
Peak sales estimate: n/a
Approved: June 1
Company: Advanced Accelerator Applications

The Scoop: Netspot, only Advanced Accelerator Applications’ second product to earn the FDA nod, is a novel PET imaging agent for the diagnosis of neuroendocrine tumors. Neuroendocrine tumors, or NETs, develop in the hormone-producing cells in the endocrine system, which occur throughout the body. These tumors can lie undetected for years, delaying diagnosis and treatment. Netspot is a sterile, single-dose kit for the preparation of gallium Ga 68 dotatate injection, a radioactive agent used to locate tumors in patients with somatostatin receptor positive NETs. Ga 68 dotatate binds to receptors on a NET in the place of the hormone somatostatin, thereby indicating the tumor's location. -- Amirah Al Idrus

13. Netspot

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.